Quarterly Result8 Aug 2026, 05:10 pm
Akums Q1 FY27 Revenue Grows 13.9% YoY to ₹1,167 Cr
AI Summary
Akums Drugs and Pharmaceuticals Ltd. reported a robust Q1 FY27 performance with a 13.9% year-on-year revenue growth to ₹1,167 crore. The company's operating profitability and PAT also saw significant increases, driven by its CDMO business. EBITDA rose by 35.4% to ₹175 crore, with margins improving to 15.0%. PAT stood at ₹101 crore, up from ₹65 crore in the prior year, with PAT margins improving to 8.4%. The CDMO segment revenue increased to ₹964 crore, contributing significantly to the overall growth. Management expressed confidence in continued growth and strengthening CDMO leadership.
Key Highlights
- Revenue increased 13.9% YoY to ₹1,167 crore in Q1 FY27.
- EBITDA grew 35.4% YoY to ₹175 crore, margin improved to 15.0%.
- PAT rose to ₹101 crore from ₹65 crore, margin improved to 8.4%.
- CDMO business remains key growth driver, revenue up to ₹964 crore.
- Management focused on CDMO leadership and operational excellence.
Price Impact
More from AKUMS